A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 for injection with Antitumor Therapy in Advanced Urothelial Carcinoma. To explore the reasonable dosage of SHR-A2102 for Advanced Urothelial Carcinoma.
Advanced Urothelial Carcinoma
DRUG: SHR-A2102|DRUG: Adebrelimab injection|DRUG: SHR-8068 injection
Phase I: RP2D of SHR-A2102 combined with Adebrelimab and SHR-8068 in patients with advanced urothelial cancer, Up to approximately 5 years|Phase I: Incidence and severity of adverse events, Up to approximately 5 years|Phase II: ORR by investigator assessment, Up to approximately 5 years
Phase I: ORR by investigator assessment, Up to approximately 5 years|Phase I: DCR by investigator assessment, Up to approximately 5 years|Phase I: DoR by investigator assessment, Up to approximately 5 years|Phase I: PFS by investigator assessment, Up to approximately 5 years|Phase I: OS by investigator assessment, Up to approximately 5 years|Phase I: Pharmacokinetic parameter for serum concentrations of SHR-A2102 and free toxin, Up to approximately 5 years|Phase I: Anti-SHR-A2102 antibody (ADA) and anti-SHR-A2102 neutralizing antibody (NAb), Up to approximately 5 years|Phase II: DCR by investigator assessment, Up to approximately 5 years|Phase II: DoR by investigator assessment, Up to approximately 5 years|Phase II: PFS by investigator assessment, Up to approximately 5 years|Phase II: OS by investigator assessment, Up to approximately 5 years|Phase II: Incidence and severity of adverse events, up to 5 years|Phase II: Pharmacokinetic parameter for serum concentrations of SHR-A2102 and free toxin, Up to approximately 5 years|Phase II: Anti-SHR-A2102 antibody (ADA) and anti-SHR-A2102 neutralizing antibody (NAb), Up to approximately 5 years
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 for injection with Antitumor Therapy in Advanced Urothelial Carcinoma. To explore the reasonable dosage of SHR-A2102 for Advanced Urothelial Carcinoma.